|Bid||0.00 x 2200|
|Ask||0.00 x 1000|
|Day's Range||12.02 - 13.25|
|52 Week Range||11.60 - 20.50|
|Beta (5Y Monthly)||0.36|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 06, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.50|
Aurinia (AUPH) delivered earnings and revenue surprises of -14.29% and -60.31%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Aurinia Pharmaceuticals (NASDAQ: AUPH), an early commercial-stage biotech, are down by 17% in after-hours trading Thursday afternoon. The biotech's stock is cratering in response to the company's 2021 first-quarter earnings report released after the closing bell today. Investors appear to be backing away from Aurinia today for one simple reason: Sales of the biotech's newly approved lupus nephritis medication Lupkynis (aka voclosporin) failed to break even $1 million during the first quarter of 2021.
Aurinia Reports First Quarter 2021 Financial Results and Recent Operational Highlights